丹麦、挪威和瑞典引入HPV疫苗前后传染病住院率:对照中断时间序列分析
该研究利用丹麦、挪威和瑞典的国家患者登记数据,采用对照中断时间序列分析,比较引入非活HPV疫苗后13岁女孩(丹麦)、8年级女孩(挪威)、7年级女孩(瑞典)与同龄男孩的传染病住院率变化。结果显示,挪威和瑞典女孩与男孩的变化相似,不支持HPV疫苗接种增加传染病住院风险;丹麦女孩与男孩的差异不太可能归因于HPV疫苗。
要点
- 在挪威和瑞典,引入HPV疫苗后女孩与男孩的传染病住院率变化相似,不支持疫苗增加非目标感染风险。
- 丹麦女孩的住院率变化与男孩不同,但结合挪威和瑞典结果,该差异不太可能归因于HPV疫苗。
- 总体而言,研究未发现HPV疫苗接种与传染病住院风险增加相关的证据。
核心结论
- 研究不支持HPV疫苗接种增加女孩传染病住院风险。
- 挪威和瑞典女孩与男孩的变化相似,与无关联一致;丹麦的差异不太可能归因于疫苗。
研究设计与样本
- 基于丹麦、挪威和瑞典国家患者登记数据的对照中断时间序列分析。
- 干预组分别为丹麦13岁女孩、挪威8年级女孩、瑞典7年级女孩;对照组为同龄或同年级男孩。
- 使用负二项回归模型估计引入HPV疫苗后住院率趋势的相对变化(水平变化,即发病率比)。
主要发现
- 任何时长传染病住院的水平变化:丹麦女孩1.21(95%CI 0.94-1.57),男孩0.73(95%CI 0.56-0.96)。
- 挪威女孩1.21(95%CI 0.94-1.56),男孩1.14(95%CI 0.88-1.49)。
- 瑞典女孩0.83(95%CI 0.65-1.07),男孩0.72(95%CI 0.56-0.92)。
- 住院≥2晚的水平变化:丹麦女孩1.05(95%CI 0.71-1.56),男孩0.81(95%CI 0.54-1.20);挪威和瑞典结果与任何时长住院相似。
临床怎么用
- 可为HPV疫苗安全性沟通提供证据,支持非活疫苗不增加非目标感染住院风险的结论。
- 在预防医学与公共卫生实践中,可引用多国登记数据的中断时间序列结果回应疫苗安全疑虑。
局限性
- 丹麦女孩与男孩的差异机制未明,但结合挪威和瑞典结果认为不太可能归因于HPV疫苗。
- 研究基于登记数据,可能受未测量混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It has been suggested that non-live vaccines may increase the risk of non-targeted infections, especially in girls. We examined whether the introduction of non-live human papillomavirus (HPV) vaccine was associated with an increased rate of infectious disease hospitalization among girls in Denmark, Norway, and Sweden. METHODS: Using data from national patient registries, we performed controlled interrupted time series analyses including an intervention group (13-year-old girls in Denmark, 8th-grade girls in Norway, 7th grade girls in Sweden) and a control group not offered HPV vaccine (boys of the same age/grade). Infectious disease hospitalization rates were modelled using negative binomial regression, and the level change, i.e. the incidence rate ratio corresponding to the relative change to the rate's underlying trend following introduction of HPV vaccine, was estimated. RESULTS: For infectious disease hospitalizations of any duration, the level change among girls and boys, respectively, was 1.21 (95% confidence interval (CI) 0.94-1.57) and 0.73 (95% CI 0.56-0.96) in Denmark; 1.21 (95% CI 0.94-1.56) and 1.14 (95% CI 0.88-1.49) in Norway; and 0.83 (95% CI 0.65-1.07) and 0.72 (95% CI 0.56-0.92) in Sweden. For hospitalizations with ≥2 overnight stays, the level change was 1.05 (95% CI 0.71-1.56) and 0.81 (95% CI 0.54-1.20) among Danish girls and boys, respectively, whereas the results in Norway and Sweden were similar to the results for hospitalizations of any duration. CONCLUSION: Changes to the rate following introduction of HPV vaccine were similar among girls and boys in Norway and Sweden, in line with there being no association between HPV vaccination and infectious disease hospitalizations. The difference between Danish girls and boys seems unlikely to be attributable to HPV vaccine, given the Norwegian and Swedish results. Overall, our study does not support that HPV vaccination increases risk of infectious disease hospitalization.
引用
- Laake I, Feiring B, Sørup S, et al. Infectious disease hospitalization rates before and after introduction of vaccine against human papillomavirus in Denmark, Norway, and Sweden: controlled interrupted time series analyses. Vaccine. 2026. PMID: 42308975. doi:10.1016/j.vaccine.2026.128851
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。